Chemed stock holds above 500 USD after strong earnings and higher dividend

Chemed stock is trading above 500 USD after the company beat its latest quarterly earnings expectations, raised its fiscal 2026 EPS guidance and increased its dividend, while the shares remain below their recent 12 month high.

Chemed Corporation stock (ISIN US1638321034) is trading around 518.80 USD as of September 1, 2026, leaving the New York Stock Exchange listed healthcare and services group with a market capitalization of about 6.77 billion USD according to recent market data.

Earnings beat and guidance for 2026

According to analyses summarized by MarketBeat, Chemed most recently reported quarterly earnings per share of 6.06 USD in results released on July 28, 2026, beating the consensus estimate of 5.60 USD by 0.46 USD for that quarter. In the same quarter, the company generated revenue of 673.25 million USD, ahead of analyst expectations of 665.04 million USD and representing an 8.8 percent increase compared with the same period a year earlier when earnings per share stood at 4.27 USD. MarketBeat notes that Chemed also issued fiscal 2026 guidance, projecting full year earnings per share in a range between 25.00 and 25.75 USD, while the sell side on average expects about 23.18 USD per share for the current fiscal year.

Profitability metrics underscore the recent earnings momentum. The same MarketBeat summary highlights that Chemed achieved a net margin of 10.60 percent and a return on equity of 31.77 percent in the latest reported quarter, indicating that the company is converting revenue into profit effectively and generating a high return on shareholders capital. For investors, the combination of high double digit return on equity and mid single digit revenue growth in the core hospice and service businesses is a key part of the equity story.

Dividend increase and analyst view

The latest shareholder return measures also point to a more generous capital allocation. As reported by MarketBeat coverage, Chemed raised its quarterly dividend from 0.60 USD to 0.70 USD per share in the current year, implying an annualized dividend of 2.80 USD and a dividend yield of about 0.5 percent for shareholders based on recent price levels. The payout ratio is cited at around 14.06 percent, which suggests that the company still reinvests the majority of its earnings for growth and operations.

Analyst sentiment on the stock remains measured despite the solid operating performance. The same MarketBeat summaries indicate that Chemed shares carry a consensus Hold rating, with an average analyst price target of about 530.75 USD. Compared with the recent trading level of approximately 518.80 USD, this implies limited upside in the near term based on current estimates, even though the stock trades on a price to earnings multiple of around 26.29 according to the latest quote data.

Stock performance and trading range

From a technical perspective, Chemed shares continue to trade in the upper part of their recent range. MarketBeat data for the latest trading session notes that the stock opened at 518.26 USD on September 1, 2026 and that Chemed Corporation has a 12 month low of 365.20 USD and a 12 month high of 557.00 USD. This means the current level is well above the 12 month low but still below the recent 12 month high, leaving room on the upside if the company can sustain earnings growth and meet its fiscal 2026 guidance.

Real time quote data compiled by Robinhood shows that on September 1, 2026 Chemed stock traded in an intraday range between 517.29 USD and 523.70 USD and closed around 518.80 USD. Within that session, the stock ended approximately 0.3 percent above the intraday low and about 0.9 percent below the intraday high, indicating relatively modest intraday volatility for investors following short term price moves.

Hospice and services business as earnings driver

Chemed Corporation operates primarily through its healthcare oriented brands, including hospice care and related service businesses in the United States, which contribute the bulk of revenue and earnings cited in the latest quarterly report summarized by MarketBeat. The revenue increase of 8.8 percent year over year to 673.25 million USD in the most recent quarter indicates that the company is growing faster than many mature healthcare service peers, while maintaining a net margin of 10.60 percent on this higher revenue base.

The company guidance for fiscal 2026 earnings per share between 25.00 and 25.75 USD implies that management expects continued profitability improvements relative to the current year analyst consensus of about 23.18 USD per share. For investors, the key question will be whether Chemed can maintain double digit return on equity near 31.77 percent while funding growth in its hospice and service network and continuing to return capital via a higher dividend.

Chemed services and customer focus

Chemed Corporation is best known for its VITAS Healthcare hospice services, which provide end of life care across the United States, and its Roto Rooter plumbing and drain cleaning business. These segments together underpin the revenue figures of 673.25 million USD in the latest quarter and the earnings per share beat of 6.06 USD cited by MarketBeat. Hospice services are typically paid through a combination of Medicare, private insurance and out of pocket payments, while Roto Rooter serves residential and commercial customers with plumbing and maintenance work.

For customers and patients, the company emphasizes service reliability and nationwide coverage, which can be important in the competitive healthcare and services markets. The combination of healthcare and home services gives Chemed a diversified revenue base, which helps explain why the company can sustain net margins above 10 percent and fund a growing dividend while still guiding for earnings per share of up to 25.75 USD in fiscal 2026.

Chemed stock and investor perspective

Chemed stock traded at approximately 518.80 USD as of September 1, 2026 on the New York Stock Exchange, corresponding to a market capitalization of about 6.77 billion USD and placing the stock near, but still below, its 12 month high of 557.00 USD reported by MarketBeat. With a price to earnings ratio near 26.29 based on current earnings and a dividend yield of about 0.46 percent following the increase of the quarterly dividend to 0.70 USD per share, the shares reflect expectations of continued earnings growth in line with the company guidance range for fiscal 2026.

For investors considering Chemed Corporation, the crucial factors include the companys ability to sustain revenue growth of around 8.8 percent year over year, to maintain a net margin of roughly 10.60 percent and to deliver on its guidance of 25.00 to 25.75 USD in earnings per share in fiscal 2026. The modest dividend yield combined with a relatively high return on equity suggests that the primary attraction of Chemed stock lies in potential long term earnings growth rather than income alone.

Key data for Chemed Corporation

• Company: Chemed Corporation
• ISIN: US1638321034
• Ticker: CHE
• Trading venue: NYSE
• Price (as of September 1, 2026): 518.80 USD
• Market capitalization: 6.77 billion USD (as of September 1, 2026)
• Sector / Industry: Healthcare services and home services
• Index membership: S and P 500